Introduction: The present study shows the processing of the pharmacopoeia article for the preparation of Di- clofenac sodium extended release matrix tablet formulated from alternative characteristic poly- mer. The matrix tablets were prepared according to traditional method of the wet granula- tion for tablet form medicine. Method: A standardization study made use of several international pharmacopoeias, such as the Mongolian National Pharmacopoeia (MNP 2011), United States Pharmacopoe- ia (USP 32), Chinese Pharmacopoeia (CP 2010) and U.S Department of F.D.A for the sub- stance’s requirements. Result: The results from this study showed a completely processed manufacturing pharma- copoeia issue of the Diclomon 100 mg retard tablet and its technological and standardized re- quirements.

Introduction:The present study shows the processing of the pharmacopoeia article for the preparation of Di- clofenac sodium extended release matrix tablet formulated from alternative characteristic poly- mer. The matrix tablets were prepared according to traditional method of the wet granula- tion for tablet form medicine.Method: A standardization study made use of several international pharmacopoeias, such as the Mongolian National Pharmacopoeia (MNP 2011), United States Pharmacopoe- ia (USP 32), Chinese Pharmacopoeia (CP 2010) and U.S Department of F.D.A for the sub- stance’s requirements.Result: The results from this study showed a completely processed manufacturing pharma- copoeia issue of the Diclomon 100 mg retard tablet and its technological and standardized re- quirements.